<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00241111</url>
  </required_header>
  <id_info>
    <org_study_id>CZOL446EFR04</org_study_id>
    <nct_id>NCT00241111</nct_id>
  </id_info>
  <brief_title>Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis</brief_title>
  <official_title>Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Study to determine effectiveness and safety of zoledronic acid and whether it has a
      pharmaco-economic impact in prostate cancer with bone metastasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to assess the effectiveness of Zol in prevention of SREs in stratified groups (hormonal treatment)</measure>
    <time_frame>at 15 months &amp; at end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to assess the effectiveness of Zol in improving pain and QoL in prostate cancer patients with bone metastases</measure>
    <time_frame>V1, V2, V3, V5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to assess the safety of ZOL treatment</measure>
    <time_frame>V1, V2, V3, V5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to assess resources consumption</measure>
    <time_frame>V1, V2, V3, V5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to assess BM</measure>
    <time_frame>V1 et V5</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Prostate Cancer With Bone Metastasis</condition>
  <arm_group>
    <arm_group_label>Zometa</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
    <arm_group_label>Zometa</arm_group_label>
    <other_name>ZOl446</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥18 years.

          -  Written informed consent.

          -  With histologically-proven prostate carcinoma.

          -  ECOG performance status ≤ 2

          -  Life expectancy &gt; 12 months

          -  Current or previously documented diagnosis of at least 1 bone metastasis due to
             prostate cancer (patient could be hormono naif, Hormono sensible or hormono
             refractory)

          -  Patients with partners of childbearing potential should use a barrier method of
             contraception throughout the study.

        Exclusion Criteria:

          -  ECOG performans status &gt;3

          -  Prior treatment with bisphosphonates IV within the last 3 month to the study

          -  Renal insufficiency (serum creatinine &gt; 265 micromol/L or &gt; 3.0 mg/dL)

          -  Liver function tests &gt; 2.5 ULN

          -  Patients with another nonmalignant disease which would confuse the evaluation of
             primary endpoints or prevent the patient from complying with the protocol.

          -  History of concomitant disease with influence on bone metabolism such as Paget's
             disease or primary hyperparathyroidism

          -  Disabling or non controlled concomitant disease likely to alter the quality of life

          -  Patient unable to fill in a questionnaire: senile dementia, psychiatric or
             neurological disease, illiterate or partially sighted patient

          -  Known hypersensitivity to zoledronic acid or other bisphosphonates

        Other protocol-defined inclusion / exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=2440</url>
    <description>Results for CZOL446EFR04 on the Novartis Clinical Trial Website</description>
  </link>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2005</study_first_submitted>
  <study_first_submitted_qc>October 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2005</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Prostate</keyword>
  <keyword>cancer</keyword>
  <keyword>bone metastasis</keyword>
  <keyword>zoledronic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

